Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions

EGFR exon 20 insertions (Ex20Ins) account for 4–10% of EGFR activating mutations in non-small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally unresponsive to 1(st) and 2(nd) generation EGFR inhibitors, and current standard of care for NSCLC patients with EGFR Ex20Ins is conventional cyto...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mol Cancer Ther
Main Authors: Floc’h, Nicolas, Martin, Matthew J., Riess, Jonathan W., Orme, Jonathan P., Staniszewska, Anna D., Menard, Ludovic, Cuomo, Maria Emanuela, O'Neill, Daniel J, Ward, Richard A., Finlay, M. Raymond V., McKerrecher, Darren, Cheng, Mingshan, Vang, Daniel P, Tsai, Rebekah A., Keck, James G., Gandara, David R., Mack, Philip C., Cross, Darren, AE
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5932243/
https://ncbi.nlm.nih.gov/pubmed/29483211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0758
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker